Risk factors for cardiovascular disease in women

Journal of Human Hypertension

Volumn 12, Issue 10, 1998, Pages 667-673

  Holdright, D R ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; Epidemiology; Risk factors; Women

Indexed keywords

CHOLESTEROL; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ESTROGEN THERAPY; FEMALE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LONGEVITY; ONSET AGE; POSTMENOPAUSE; REVIEW; RISK FACTOR; SMOKING; SOCIAL CLASS;

EID: 0031730889     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000696     Document Type: Review

References (63)

1. Bowker TJ et al. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996; 75: 334-342.
2. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26 year follow-up of the Framingham population. Am Heart J 1986; 111: 383-390.
3. National Centre for Health Statistics. Vital statistics of the United States, 1989. Vol. II. Mortality. Part A. Washington, DC: Government Printing Office. 1993. (DHHS publication no. (PHS) 93-1101.)
4. Grady D et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037.
5. Wenger NK. Coronary heart disease: an older woman's major health risk, Br Med J 1987; 315: 1085-1090.
6. Pilote L, Hlatky MA. Attitude of women toward hormone therapy and prevention of heart disease. Am Heart J 1995; 129: 1237-1238.
7. Health of the Nation Working Group. Variations in health. What can the Department of Health and the NHS do? Department of Health: London, 1995.
8. Kelly DT. Our future society. A global challenge. Circulation 1997; 95: 2459-2464.
9. Thom TJ. Cardiovascular disease mortality among United States women. In: Eaker ED et al (eds). Coronary Heart Disease in Women. National Heart, Lung, and Blood Institute, National Institute of Health: Bethesda, Md, 1987.
10. Murabito JM, Evans JC, Larson MG, Levy D. Prognosis after the onset of coronary heart disease. An investigation of differences in outcome between the sexes according to initial disease presentation. Circulation 1993; 88: 2548-2555.
11. Isles CG, Hole DJ, Hawthorne VM, Lever AF. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men. Lancet 1992; 339: 702-706.
12. Tunstall-Pedoe H et al. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish heart health study: cohort study. Br Med J 1997; 315: 722-729.
13. Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990; 12: 321-331.
14. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med 1995; 332: 1758-1766.
15. Moreno GT, Manson JE. Cholesterol and coronary heart disease in women: an overview of primary and secondary prevention. Cor Art Disease 1993; 4: 580-587.
16. Jacobs DR Jr et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990; 131: 32-47.
17. Hong MK et al. Usefulness of the total cholesterol to high-density lipoprotein cholesterol ratio in predicting angiographic coronary artery disease in women. Am J Cardiol 1991; 68: 1646-1650.
18. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987; 114: 413-419.
19. Stensvold I, Tverdal A, Urdal P, Graff-Iversen S. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. Br Med J 1993; 307: 1318-1322.
20. Orth-Gomer K et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation 1997; 95: 329-334.
21. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
22. Sacks FM et al for the Cholesterol and Recurrent Events Trial Investigators (CARE). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
23. Anastos K et al. Hypertension in women: what is really known? Ann Intern Med 1991; 115: 287-293.
24. Stamler J et al. Hypertension screening of 1 million Americans. Community hypertension evaluation clinic (CHEC) program, 1973 through 1975. JAMA 1976; 235: 2299-2306.
25. Cornoni-Huntley J, LaCroix AZ, Havlick RJ. Race and sex differentials and the impact of hypertension in the United States. The National Health and Nutrition Examination Survey 1 Epidemiologic Follow-up Study. Arch Intern Med 1989; 149: 870-878.
26. Liao Y, Cooper RS, Mensah GA, McGee DL. Left ventricular hypertrophy has a greater impact on survival in women than in men. Circulation 1995; 92: 805-810.
27. Levy D et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-1562.
28. Kojima S et al. A gender difference in the association between salt sensitivity and family history of hypertension. Am J Hypertens 1992; 5: 1-7.
29. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 1982; 248: 1465-1477.
30. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo Study. Am J Med 1980; 69: 725-732.
31. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90-114 mmHg. JAMA 1970; 213: 1145-1182.
32. Hayes SH, Taler SJ. Hypertension in women: current understanding of gender differences. Mayo Clin Proc 1998; 72: 157-165.
33. MRC trial of mild hypertension: principal results. Medical Research Council Working Party. Br Med J 1985; 291: 197-204.
34. Hypertension Detection and Follow-Up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program II. Mortality by race, sex and age. JAMA 1979; 242: 2572-2577.
35. Hypertension Detection and Follow-up Program Cooperative Group. Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-Up Program. JAMA 1988; 259: 2113-2122.
36. The Australian therapeutic trial in mild hypertension: report by the management committee. Lancet 1980; 1: 1261-1267.
37. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: 405-412.
38. Amery A, Brixko R, Clement D et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1: 1349-1354.
39. Dahlof B et al. Swedish trial in Old Patients with Hypertension (STOP-Hypertension) analyses performed up to 1992. Clin Exp Hypertens 1993; 15: 925-939.
40. SHEP cooperative Research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
41. Neaton JD et al. (Treatment of Mild Hypertension Study Research Group). Treatment of Mild Hypertension Study: final results. JAMA 1993; 270: 713-724.
42. Wuerst JH Jr, Dry TJ, Edwards JE. The degree of coronary atherosclerosis in bilaterally oophorectomised women. Circulation 1958; 7: 801-809.
43. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63.
44. Coronary Drug Project Research Group. The Coronary Drug Project: findings leading to modifications of its research protocol. JAMA 1970; 214: 1303-1313.
45. Royal College of General Practitioners' Oral Contraception Study: further analyses of mortality in oral contraceptive users. Lancet 1981; 1: 541-546.
46. Smith DC, Prentice R, Thompson DJ, Herrman WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975; 293: 1164-1167.
47. The Writing group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199-208.
48. Van Buren GA, Yang D, Clark KE. Estrogen-induced uterine vasdilatation is antagonised by L-nitroarginine methyl ester and inhibitor of nitric oxide synthesis. Am J Obstet Gynecol 1992; 167: 828-833.
49. Sugioka K, Shimosegawa Y, Nakano M. Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEBS Lett 1987; 210: 37-39.
50. Kawas C et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore longitudinal study of aging. Neurology 1997; 48: 1517-21.
51. Reducing the health consequences of smoking: 25 years of progress: a report of the Surgeon General. 1989. Rockville, Md.: Department of Health and Human Services, 1989. (DHSS publication no. (CDC) 89-8411).
52. Willett WC et al. Relation and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987; 317: 1303-1309.
53. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 1990; 322: 213-217.
54. Prescott E et al. Smoking and risk of myocardial infarction in women and men: longitudinal population study. Br Med J 1998; 316: 1043-1047.
55. Foulds J, Godfrey C. Counting the costs of children's smoking. Br Med J 1995; 311: 1152-1154.
56. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA 1979; 241: 2035-2038.
57. Pan WH et al. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol 1986; 123: 504-516.
58. Manson JE et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141-1147.
59. Manson JE et al. Body weight and mortality among women. N Engl J Med 1995; 333: 677-685.
60. Sherman SE, D'Agostino RB, Cobb JL, Kannel WB. Physical activity and mortality in women in the Framingham Heart Study. Am Heart J 1994; 128: 879-884.
61. Osmond C et al. Early growth and death from cardiovascular disease in women. Br Med J 1993; 307: 1519-1524.
62. Razay G, Heaton KW, Bolton CH, Hughes AO. Alcohol consumption and its relation to cardiovascular risk factors in British women. Br Med J 1992; 304: 80-83.
63. Kushi LH et al. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996; 334: 1156-1162.